Nov 16, 2022 / 04:00PM GMT
Jacob K. Johnson - Stephens Inc., Research Division - MD & Analyst
All right. Good morning, everybody. Welcome to day 2 of the Stephens Conference. I'm Jacob Johnson, the life science tools and pharma services analyst here at Stephens. Pleased to be joined by Catalent this morning. We have CFO, Tom Castellano; and Paul Surdez from IR, who made the trip from their, I believe, their annual executive meeting. So really happy to have you all here today. Thank you for joining us.
Tom, maybe I'll turn it over to you for any opening comments you'd like to make, and then we'll launch into Q&A.
Thomas P. Castellano - Catalent, Inc. - Senior VP & CFO
Yes, that sounds great. So thanks, Jacob. Thanks, everyone. Just want to first call out the normal forward-looking statements disclosure that can be found in our SEC filings available on our Investor Relations website.
So look, I think coming off of what was clearly a little bit of a mixed print 2 weeks ago, since then, we've received, I would say, some very helpful investor feedback, and I know
Catalent Inc at Stephens Investment Conference Transcript
Nov 16, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers